Midday: Memory Gives Back, Money Rotates to Biotech and Space
SignalDeck Midday Scan · Friday, June 26, 2026
Situational Awareness
🔻 The memory pop is unwinding. A day after Micron’s blowout lit the complex, it’s reversing: Micron −4.7%, SanDisk −5%, and Western Digital −10.5% are giving back the rally. The broad tape is risk-off — Nasdaq −1.25%, S&P −0.75% — even as the Russell 2000 trades green (+0.7%) on reconstitution flows.
📅 Russell reconstitution finalizes at today’s close. The semi-annual rebalance drives forced index buying and selling into the bell — the small-cap strength is mechanical, not fundamental.
🏭 ON Semi −22.6% after announcing a $7B acquisition of Synaptics — a reminder that on a catalyst-heavy day the buyer often pays the price. Bloom Energy −13.6% is also pulling back from its run.
🏦 OpenAI reportedly delaying its IPO to 2027 (weighing a $1T valuation later vs. a lower one sooner) — a sentiment damper on the late-stage AI-IPO trade.
Top Calls
Risk-off, semis-down — and the money rotated to biotech and speculative growth. Only one clean fresh-EP today (WSE); the rest are news-driven catalysts (no EP-γ — their earnings inputs are stale).
WSE +8.7% · fresh-EP · CAND (EP-γ 59 / 56) · Med — Wise (the cross-border fintech) reported FY26: net revenue +19% to $2.5B, active customers +21% to 18.9M, and a new $500M+ buyback. Strong volume (rVol 4.75) but a revenue miss vs. estimate capped the score. The one real earnings setup on the board.
FCEL +25% · news_driven (analyst + contract) · Med — FuelCell Energy on a Jefferies upgrade to Buy (PT $24) plus its first contracted US data-center power deal — a 380MW Fit Energy agreement with an immediate deposit on the first 30MW (~$90M near-term revenue). The “show-me” story is starting to execute.
MRNA +10–13% · news_driven (regulatory) · Med — Moderna after an FDA advisory committee’s unanimous 9-0 vote backing its mRNA flu vaccine for adults 50+, ahead of an August PDUFA date — plus a Science Day reframing the post-COVID pipeline.
ASTS +10% · news_driven (milestone) · Med — AST SpaceMobile on a successful BlueBird 8/9/10 satellite launch (Block 2, the largest commercial comms arrays in orbit), moving its direct-to-phone network from testing toward service.
SLS +14.6% · news_driven (M&A speculation) · Low — SELLAS Life Sciences on executive contract changes (often read as takeover prep) ahead of a Phase 3 REGAL AML readout sitting at 78 of 80 required events. Speculative.
The Setups
WSE
Wise · the lone clean earnings setup on a chaotic tape. Wise — the cross-border money-transfer fintech — reported FY2026 with net revenue up 19% to $2.5B, active customers up 21% to 18.9 million, cross-border volume up 31% to $243.5B, and a new buyback intention above $500M. Why it scored only a CAND despite an 18% EPS beat: revenue came in slightly below estimate (the take rate eased to 0.52%), which capped the earnings component, and as a foreign ADR it carries no relative-strength cohort data in the model. What the price reflects: +8.7% on nearly 5x average volume is real institutional participation in a genuine growth-and-capital-return story, not a thin gap.
FCEL
FuelCell Energy · the story turns from “show me” to “executing.” Two catalysts stacked: Jefferies upgraded the stock to Buy with a $24 target, and the company landed its first contracted US data-center power order — a 380MW agreement with Fit Energy, with an immediate non-refundable deposit on an initial 30MW deployment (roughly $90M of near-term revenue). The significance is the category: AI data centers needing on-site power is a new, large demand pool for fuel cells, and a contracted order with a deposit is harder evidence than a pipeline number. The +25% reflects the market repricing a perennial money-loser as a name with visible, funded backlog.
MRNA / ASTS / SLS — the rotation names
Three different stories, one common thread: money leaving chips for catalyst-driven growth. Moderna got a clean regulatory win (a unanimous FDA panel vote on its flu vaccine, de-risking an August decision). AST SpaceMobile hit a hard operational milestone (a successful three-satellite launch advancing its direct-to-smartphone network). SELLAS is pure M&A-and-data speculation ahead of a Phase 3 readout. None reported earnings today, so none carries an EP score — these are news and milestone catalysts, and on a day the AI-memory trade is unwinding, that’s where the speculative money rotated.
Bottom line: A risk-off Friday where yesterday’s memory winners gave back and the bid rotated into biotech (MRNA), space (ASTS), and power (FCEL). The only clean earnings setup is WSE — a real fintech growth-and-buyback story held back only by a light revenue line. Watch the close for Russell-reconstitution distortion.
Live intraday as of 1:35 PM ET (10:35 AM PT) · midday market scan.
Brought to you by SignalDeck.live.
Not financial advice. SignalDeck surfaces catalysts and what price and volume reflect — how any of these trade is up to the market. Do your own diligence.